Blood tests and patient surveys could improve bile duct cancer monitoring
NCT ID NCT07454486
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to learn if blood tests for cancer DNA (ctDNA) and patient-reported quality of life can help doctors predict how bile duct cancer will progress and whether treatments are working. Researchers will collect blood samples and surveys from 300 patients with curable or incurable bile duct cancer. The goal is to find better ways to monitor the disease than standard CT scans, which can be unreliable for this cancer type.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER (BTC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Aarhus University Hospital
Aarhus, 8220, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a vaccine help fight Hard-to-Treat cancers?
- A new test could reveal how radiation affects the liver
- Can matching cancer drugs to tumor genes prevent biliary tract cancer return?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- Can a smart drug home in on Hard-to-Treat GI cancers?
- Can a dual immune booster plus chemo shrink hard-to-treat bile duct tumors?